Co-delivery of TLR7/8 agonists and TGF-β inhibitors (TGFβi) has the potential to overcome immunosuppression in the tumor microenvironment. Here the authors describe the application of the CarboCell technology for the sustained intratumoral release of a TLR7/8 agonist alone or in combination with a TGFβi, promoting anti-tumor immune responses in preclinical cancer models.
- Sophie B. Jensen
- Ditte E. Jæhger
- Thomas L. Andresen
